Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Praxis Precision Medicines (PRAX) Gains from Investment Securities (2022 - 2025)

Historic Gains from Investment Securities for Praxis Precision Medicines (PRAX) over the last 4 years, with Q3 2025 value amounting to $52000.0.

  • Praxis Precision Medicines' Gains from Investment Securities rose 510000.0% to $52000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year increase of 81474.36%. This contributed to the annual value of $308000.0 for FY2024, which is 12481.75% up from last year.
  • Latest data reveals that Praxis Precision Medicines reported Gains from Investment Securities of $52000.0 as of Q3 2025, which was up 510000.0% from $23000.0 recorded in Q2 2025.
  • In the past 5 years, Praxis Precision Medicines' Gains from Investment Securities ranged from a high of $1.2 million in Q1 2025 and a low of $1000.0 during Q3 2023
  • Moreover, its 4-year median value for Gains from Investment Securities was $16000.0 (2022), whereas its average is $131666.7.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first crashed by 8571.43% in 2023, then soared by 510000.0% in 2025.
  • Over the past 4 years, Praxis Precision Medicines' Gains from Investment Securities (Quarter) stood at $7000.0 in 2022, then fell by 28.57% to $5000.0 in 2023, then surged by 3040.0% to $157000.0 in 2024, then crashed by 66.88% to $52000.0 in 2025.
  • Its Gains from Investment Securities stands at $52000.0 for Q3 2025, versus $23000.0 for Q2 2025 and $1.2 million for Q1 2025.